Medzown is precision medicine management at scale. We use advanced analytics and deep expertise to bridge the gap between patients and treatments like immunotherapies, targeted therapies, cell and gene therapies, and clinical trials. At the same time, we deliver exceptional return on investment for payers, providers, and pharma.
External link for Medzown
Jupiter, FL 33458, US
Healthcare Start-Up COO ⎸ Leadership ⎸ Operational Excellence ⎸ Culture Creation ⎸ Scale & Growth
Are you ready to take the next big step in your career? We're searching for a dynamic, growth-minded professional who is eager to make an impact and take on more responsibility. If you thrive in a collaborative, supportive environment and are looking for a role where you can be both challenged and mentored, this is the opportunity you've been waiting for!
Jennifer Levin Carter MD, MPH, MBA has a new article in Employee Benefit News explaining how precision medicine can help payers and self-insured employers curb the costs of life-saving cell and gene therapies. I think it's worth the time to read.
With as many as 4,000 cell, gene, and ribonucleic acid therapies estimated to be in development by 2030, group health plans are under more financial pressure than ever to find long-term solutions. Making cell and gene therapies more accessible and affordable raises the bar on stewardship because it's ultimately in members' best interest. It enables group health plans to fulfill their fiduciary responsibilities under the Consolidated Appropriations Act. In the third article in a series in Employee Benefit News, our founder and CEO, Jennifer Levin Carter MD, MPH, MBA, shares how precision medicine, access to advanced treatments, and clinical trials can significantly reduce expensive cell and gene therapy claims while improving care. https://lnkd.in/gCeXBJHk #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy
With as many as 4,000 cell, gene, and ribonucleic acid therapies estimated to be in development by 2030, group health plans are under more financial pressure than ever to find long-term solutions. Making cell and gene therapies more accessible and affordable raises the bar on stewardship because it's ultimately in members' best interest. It enables group health plans to fulfill their fiduciary responsibilities under the Consolidated Appropriations Act. In the third article in a series in Employee Benefit News, our founder and CEO, Jennifer Levin Carter MD, MPH, MBA, shares how precision medicine, access to advanced treatments, and clinical trials can significantly reduce expensive cell and gene therapy claims while improving care. https://lnkd.in/gCeXBJHk #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy
With high-cost claimants accounting for just 5% of the population but driving as much as half of all medical bills, precision medicine is key to improving care and significantly reducing the cost of care for people with cancer, rare diseases, and other complex, debilitating and life-threatening conditions increasingly treated with drugs like immunotherapies and cell and gene therapies. In the second article in a series in Employee Benefit News, our Founder and CEO, Jennifer Levin Carter MD, MPH, MBA shares how precision medicine and access to advanced treatments and clinical trials can significantly reduce these expensive claims while improving care. https://lnkd.in/gSqisdEN #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy
Don't miss this exciting panel discussion tomorrow morning at 10:45 ET at SCOPE's Clinical Trial in Tech Conference in Orlando, Florida. #precisionmedicine
Will you be at SCOPE’s Clinical Trial in Tech Conference? Join Jennifer Levin Carter MD, MPH, MBA, along with Arnon Horev, John Pavletic, Peter Lafer, and Brigham Hyde for the panel discussion: Representative Data on the 30th Anniversary of the NIH Revitalization Act. Learn more and register here: https://lnkd.in/eJkanrPK
We're #hiring a Head of Product to join our growing team. Know anyone who might be interested? https://lnkd.in/dSGBUqN4
Will you be at SCOPE’s Clinical Trial in Tech Conference? Join Jennifer Levin Carter MD, MPH, MBA, along with Arnon Horev, John Pavletic, Peter Lafer, and Brigham Hyde for the panel discussion: Representative Data on the 30th Anniversary of the NIH Revitalization Act. Learn more and register here: https://lnkd.in/eJkanrPK
Our Founder and CEO, Jennifer Levin Carter MD, MPH, MBA shares how precision medicine is one of the most promising and novel approaches to controlling excessive healthcare costs and providing a meaningful benefit through improved disease diagnosis, treatment, and prevention in the latest Employee Benefit News issue. http://bit.ly/493v3BT #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy
We’re #hiring a Patient Navigator to join our growing team. Know anyone who might be interested?